Cardiotoxicity in childhood cancer survivors: A problem with long-term consequences in need of early detection and prevention

Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective

(2013) Etan Orgel et al.   PEDIATRIC BLOOD & CANCER

Screening for Long-Term Cardiac Status During Cancer Treatment

(2012) Steven E. Lipshultz et al.   Circulation-Cardiovascular Imaging

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

(2012) Steven E. Lipshultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database

(2012) Dana M. Walker et al.   PEDIATRIC BLOOD & CANCER

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes

(2012) S. E. Lipshultz et al.   PEDIATRICS

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium

(2011) Lynda M. Vrooman et al.   EUROPEAN JOURNAL OF CANCER

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY